Immunoglobulin human antiresus Rho (D) (Immune globulin human antirhesus Rho [D])

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Immunoglobulins

Included in the formulation
  • HyperROU® S / D
    solution w / m 
    Grifols Therapyutics Inc.     USA
  • Immunoro Kedrion
    lyophilizate w / m 
    Kedrion SpA     Italy
  • KAMROU
    solution w / m 
    Kamada Co., Ltd.     Israel
  • Partobulin SDP
    solution w / m 
    Baxter AG     Austria
  • Rezogam® H
    solution w / m in / in 
    CESEL Behring AG     Switzerland
  • Resonative
    solution w / m 
    Octapharma AB     Sweden
    • Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

    VED

    АТХ:

    J.06.B.B.01   Immunoglobulin human antiresus Rho (D)

    Pharmacodynamics:

    Contains the active component of immunoglobulin G, which contains incomplete anti-Rho (D) -antibodies. Prevents isoimmunization of Rho (D) -negative mother after the birth of a child with Rh-positive blood accessory, with early termination of pregnancy (spontaneous or artificial), getting a penetrating wound of the abdomen or performing an amniocentesis during pregnancy.

    Pharmacokinetics:

    After intramuscular injection, the maximum concentration in the blood plasma is reached after 24 hours.

    The half-life of the immunoglobulin is 23-26 days; the half-life of antibodies is 4-5 weeks.

    Indications:

    It is used for the prevention of Rh-conflict in women with Rh-negative blood belonging not sensitized to the antigen Rh0(D): gave birth to the first child with positive rhesus, with compatibility with the blood of the mother in the group AB0 or ​​after abortion with Rh positive of the blood of the husband.

    ICD-10

    XV.O30-O48.O36.0   Rhesus-immunization, requiring the provision of medical care to the mother

    Contraindications:

    Rodilnitsy with Rh-negative blood accessory, in the serum of which Rhesus antibodies were detected; newborns.

    Carefully:

    Individual hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - Category B. It is used in pregnancy and lactation.

    Dosing and Administration:

    Intramuscularly once, one dose (300 mg) of the parturient mother within 48-72 hours after delivery or immediately after the abortion, amniocentesis, or in the third trimester of pregnancy.

    The highest daily dose: 300 mg.

    The highest single dose: 300 mg.

    Side effects:

    Hyperthermia within the first 24 hours after drug administration, dyspepsia, allergic reactions.

    Overdose:

    Cases of overdose are not described.

    Treatment is symptomatic.

    Interaction:

    Compatible with drugs from all groups, including antibiotics.

    Special instructions:

    Immunization of women with live vaccines is carried out 3 months after the administration of antiresus immunoglobulin.

    Instructions
    Up